What Wall Street Recommends for Amarin after Q4 2018 Results

On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33. Its market capitalization was $6.00 billion.

Amarin reported revenues of $77.33 million in the fourth quarter, a year-over-year rise of 43.5% and higher than the consensus estimate by $3.46 million The company also reported an adjusted loss per share of $0.09 in the fourth quarter, a year-over-year deterioration of 28.57% and lower than the consensus estimate by $0.02.

Based on its closing price on February 27, the company reported returns of 23.14% in the last week, 25.55% in the last month, 10.31% in the last quarter, 664.62% in the last half-year, 472.43% in the last year, and 55.62% year-to-date.

Based on its closing price on February 27, the broader healthcare sector, represented by the Health Care Select Sector SPDR ETF (XLV), reported returns of -0.65% in the last week, 4.56% in the last month, 2.54% in the last quarter, 0.03% in the last half-year, 6.38% in the last year, and 6.25% year-to-date.

Amarin has significantly outperformed XLV in 2018 as well as in 2019 year-to-date.

The 12-month consensus recommendation for Amarin is a “strong buy” while peers Abbott Laboratories (ABT), GlaxoSmithKline (GSK), and FibroGen (FGEN) have “buy,” “buy,” and “strong buy” ratings, respectively.

While two analysts rate Amarin a “strong buy,” the remaining two rate the company a “buy.” The 12-month target price is projected at $34.00, 60.53% higher than its last closing price on February 27. The highest, median, and lowest target price estimates for the company are $51, $32.50, and $20, respectively.

Next in this series, we’ll discuss the company’s revenue performance in fiscal 2018.